Prasol Chemicals IPO Review: Key Details, Company Overview and Financials

The Prasol Chemicals IPO is a bookbuilding issue of Rs 500 crore, comprising a fresh issue of shares worth Rs 80 crore and an offer for sale of 62,13,006 equity shares worth Rs 420 crore by the promoter family and other existing shareholders. The IPO will open for subscription on 8 September 2026 and close on 10 September 2026. The allotment is expected to be finalised on 11 September 2026, while the shares are proposed to list on BSE and NSE around 16 September 2026.

The Prasol Chemicals IPO price band is set at Rs 643 to Rs 676 per share, with a lot size of 22 shares. Retail investors must apply for a minimum of 22 shares, requiring an investment of Rs 14,872, and can apply for up to 13 lots (286 shares, Rs 1,93,336). HNI investors need to apply for at least 14 lots, or 308 shares, amounting to Rs 2,08,208.

Dam Capital Advisors Ltd. is the sole book-running lead manager for the Prasol Chemicals IPO, while Kfin Technologies Ltd. is the registrar to the issue.

For detailed information on the company's business, financials, risk factors and the proposed utilisation of proceeds, investors should refer to the Prasol Chemicals IPO Red Herring Prospectus (RHP) before making an investment decision.

Click Here – Get Free Investment Predictions

Company Overview

Incorporated in 1992, Prasol Chemicals operates in the specialty chemicals industry, manufacturing over 150 specialty chemicals, including 21 acetone-based chemicals, 53 phosphorous-based chemicals and 76 other specialty products such as surfactants, esters and acids. These products serve five major end industries: performance chemicals, paints-inks-construction-adhesives (PICA), pharmaceuticals, agrochemicals, and home and personal care.

The company operates two manufacturing facilities at Khopoli and Mahad in Maharashtra, with an aggregate annual capacity of 98,644 metric tonnes. Its customer base includes Alembic Pharmaceuticals, Lubrizol India, Rossari Biotech, Clean Science, Gharda Chemicals, Croda India, Supriya Lifescience and Yasho Industries, among others. As of 31 July 2026, Prasol Chemicals served more than 1,600 customers and exported to 69 countries, and is certified as a 3 Star Export House by the Indian government, with a distribution network across the Asia-Pacific, North and South America, and Europe.

IPO Details

Particulars	Details
IPO Date	8 to 10 September 2026
Allotment	Fri, 11 September 2026
Listing Date	Wed, 16 September 2026 (tentative)
Face Value	Rs 2 per share
Price Band	Rs 643 to Rs 676
Lot Size	22 Shares
Issue Type	Bookbuilding IPO
Sale Type	Fresh Issue cum Offer for Sale
Total Issue Size	73,96,437 shares (agg. up to Rs 500 Cr)
Fresh Issue	11,83,431 shares (agg. up to Rs 80 Cr)
Offer for Sale	62,13,006 shares (agg. up to Rs 420 Cr)
Investor Reservation	QIB: not more than 50%; Retail: not less than 35%; NII (HNI): not less than 15% of the offer
Shareholding Pre-Issue	5,80,00,000 shares
Shareholding Post-Issue	5,91,83,431 shares
Listing Exchange	BSE, NSE

(Compiled from the RHP/DRHP and market updates)

Industry Context

• India's overall chemicals sector is estimated at roughly USD 180 to 240 billion as of 2025-26 and is projected to grow at 9 percent or more annually, with industry estimates pointing toward a market of over USD 300 billion by 2030.
• The specialty chemicals segment, which Prasol Chemicals operates in, is growing faster than the broader chemicals industry, with various estimates placing India-specific specialty chemicals CAGR between roughly 5 and 12 percent depending on scope and time frame.
• India's specialty chemicals export market was valued at about USD 35.4 billion in 2026 and is forecast to nearly triple to about USD 86.2 billion by 2035, driven by the global China-Plus-One sourcing shift and new trade agreements.
• Agrochemicals, pharmaceuticals and personal care remain the largest demand drivers for specialty chemicals in India, supported by growing agricultural modernisation and India's position as a global generics and vaccine manufacturing hub.
• Government initiatives such as Make in India and Atmanirbhar Bharat, alongside global supply chain de-risking away from China, are creating capacity expansion opportunities for established Indian specialty chemical manufacturers.

Business Strengths

Here are the key strengths investors evaluating the Prasol Chemicals IPO should weigh:

• A highly diversified product portfolio of over 150 specialty chemicals used across five major application industries, reducing dependence on any single end market.
• Well established R&D capabilities and a strong pipeline of products supporting continued innovation.
• Long standing relationships with a diversified, well recognised customer base, including Alembic Pharmaceuticals, Lubrizol India and Rossari Biotech, alongside export reach to 69 countries.
• A robust financial track record, with FY26 revenue up 22 percent and profit after tax up 91 percent, supported by low borrowings at a debt-to-equity ratio of 0.19.

Screen specialty chemicals and industrial stocks on the Univest Screener

Business Risks

Alongside these strengths, the Prasol Chemicals IPO also carries the following business risks:

• The offer for sale accounts for Rs 420 crore of the Rs 500 crore issue, roughly 84 percent, meaning the bulk of proceeds go to the promoter family and other selling shareholders rather than the company.
• Specialty chemical manufacturing depends on volatile raw material inputs, including acetone and phosphorous derivatives, which can compress margins.
• The company's public KPI disclosure in the RHP shows only FY26 return ratios, limiting the ability to assess multi-year trends in ROE and ROCE.
• At the upper price band, the issue is valued at close to 47 times FY26 earnings per independent analysis, a full valuation that leaves limited margin of safety.

Financial Performance

The Prasol Chemicals IPO comes after a period of steady growth. The company's revenue increased by around 22 percent and profit after tax rose by around 91 percent between the year ended 31 March 2025 and 31 March 2026.

Prasol Chemicals Ltd. – Financials (Rs in Lakh)

Particulars	Fiscal 2026	Fiscal 2025	Fiscal 2024
Revenue from Operations	1,23,785.00	1,01,554.00	88,756.00
EBITDA	13,932.00	8,777.00	6,053.00
EBITDA Margin (%)	11.30%	8.64% (computed)	6.82% (computed)
Profit After Tax (PAT)	8,312.00	4,357.00	1,813.00
Debt-to-Equity Ratio	0.19	0.27 (computed)	0.25 (computed)
Return on Capital Employed (ROCE) (%)	22.43%	Not separately disclosed	Not separately disclosed
Return on Equity (ROE) (%)	20.37%	Not separately disclosed	Not separately disclosed

Amounts in Rs Lakh unless stated otherwise, compiled from the Prasol Chemicals IPO RHP. FY2026 financials are presented on a standalone basis while FY2025 and FY2024 reflect the company's broader restated figures; EBITDA margin and debt-to-equity for FY2025 and FY2024 are computed from disclosed absolute figures. ROCE and ROE for FY2025 and FY2024 were not separately disclosed in the available RHP data.

Key Ratios and Metrics

The table below summarises the key ratios and metrics relevant to the Prasol Chemicals IPO as of the latest reported period.

KPI (Mar 31, 2026)	Value
Return on Equity (ROE)	20.37%
Return on Capital Employed (ROCE)	22.43%
Debt-to-Equity Ratio	0.19
Return on Net Worth (RoNW)	18.53%
PAT Margin	6.74%
EBITDA Margin	11.30%
Net Asset Value (NAV per share)	Rs 77.33

Objects of the Offer

The company proposes to utilise the net proceeds from the Prasol Chemicals IPO towards the following objects.

• Repayment and/or pre-payment, in full or part, of certain borrowings availed by the company (Rs 60.00 Cr)
• General corporate purposes

Download the Univest iOS App or Univest Android App to track the Prasol Chemicals IPO and get daily stock recommendations.

Conclusion

The Prasol Chemicals IPO reflects a well diversified specialty chemicals manufacturer with a broad 150-plus product portfolio, an established R&D base, a blue-chip customer list, and a strong FY26 financial performance backed by low borrowings.

However, the large offer for sale component, raw material price sensitivity, limited multi-year return-ratio disclosure, and a fairly full valuation are factors that could affect the investment case for the Prasol Chemicals IPO.

Overall, investors weighing the Prasol Chemicals IPO should evaluate the company's business model, financial performance, industry outlook, competitive positioning, valuation and risk factors in detail, and carefully review the Red Herring Prospectus (RHP) before making an informed investment decision.

Univest does not publish grey market premium figures. Grey market premium is an unofficial and unregulated indicator collected informally outside the stock exchanges. It is not published, verified or endorsed by SEBI, NSE or BSE, can vary widely between trackers, and is not always accurate.

FAQs

What are the Prasol Chemicals IPO dates?

Ans. The Prasol Chemicals IPO will open for subscription on 8 September 2026 and close on 10 September 2026. The allotment is expected to be finalised on 11 September 2026, with the shares proposed to list on BSE and NSE around 16 September 2026.

What is the issue price and minimum investment for the Prasol Chemicals IPO?

Ans. The Prasol Chemicals IPO price band is Rs 643 to Rs 676 per share, with a lot size of 22 shares. Retail investors must apply for a minimum of 22 shares, requiring an investment of Rs 14,872 at the upper price band.

What does Prasol Chemicals Limited do?

Ans. Incorporated in 1992, Prasol Chemicals manufactures over 150 specialty chemicals, including acetone-based, phosphorous-based and other specialty products, serving industries such as performance chemicals, paints and coatings, pharmaceuticals, agrochemicals, and personal care.

How will Prasol Chemicals use the IPO proceeds?

Ans. The net proceeds from the fresh issue will primarily be used for repayment or pre-payment of certain borrowings, along with general corporate purposes.

What are the key strengths of Prasol Chemicals Limited?

Ans. Key strengths include a highly diversified specialty chemicals portfolio, established R&D capabilities, long standing relationships with a blue-chip customer base, and a robust financial track record with low borrowings.

What are the major risks associated with the Prasol Chemicals IPO?

Ans. The IPO has a large offer for sale component making up around 84 percent of the issue, the business is exposed to volatile raw material prices, multi-year return-ratio disclosure is limited, and the issue is priced at a full valuation.

Who are the lead manager and registrar for the Prasol Chemicals IPO?

Ans. Dam Capital Advisors Ltd. is the sole book-running lead manager for the Prasol Chemicals IPO, while Kfin Technologies Ltd. is the registrar to the issue.

Is the Prasol Chemicals IPO a good investment?

Ans. Prasol Chemicals offers exposure to a diversified, export-oriented specialty chemicals business with strong FY26 growth, but the large offer for sale and full valuation warrant a careful, selective approach. Investors should review the RHP and assess their own risk profile before applying.